Selatinib
Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1].
Product Specifications
CAS Number
1275595-86-2
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/selatinib.html
Purity
98.56
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(C)CCNCC1=CC=C(O1)C2=CC3=C(N=CN=C3C=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5
Molecular Formula
C29H26ClFN4O3S
Molecular Weight
565.06
Precautions
H315, H319, H320
References & Citations
[1]Meng-Na Wang, et al. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Invest New Drugs. 2020 Dec;38 (6) :1826-1835.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
